Recurrences

In conjunction with PEX and immunosuppression, CABLIVI resulted in significantly fewer recurrences requiring reinitiation of PEX²

Incidence of recurrences during treatment and throughout the 28-day follow-up post-treatment period² 

6 patients required reinitiation of PEX after treatment with CABLIVI was stopped²

• These patients had ADAMTS13 activity levels <10%, indicating the underlying disease was still active when treatment was stopped

Suppressed ADAMTS13 activity may signify the need to extend CABLIVI treatment² 

CABLIVI† led to a 67% reduction in exacerbations or relapses vs PEX and immunosuppression alone (P<0.001)²

*Percentages are based on 71 subjects entering the study drug treatment period and 66 subjects in the follow-up period.² 
†In conjunction with PEX and immunosuppression. 
ADAMTS13=a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 13.